NAMPT Inhibitors Exhibit Excellent Potency and ADME Properties05522Novel Nampt inhibitors deliver strong potency and favorable ADME, enabling chemotherapy and immune support benefits.Technology TypeTherapeutic ModalityTechnology SubtypeSmall MoleculeTherapeutic AreasImmunologyOncologyTagsAutoimmuneImmuno-oncologyLead InventorBeibei ChenDepartmentMed-MedicineAll Tech InnovatorsBeibei ChenToren FinkelYuan LiuTechnology Readiness Level3. Initial proof of concept, in-vivoDate Submitted2020-10-06
Novel Activators of AMP-activated Protein Kinase03887New nanomolar small molecules block AMPK ubiquitination, stabilizing and activating AMPK to treat metabolic, inflammatory, and cancer disorders.Technology TypeTherapeutic ModalityTechnology SubtypeSmall MoleculeTherapeutic AreasCardiovascularEndocrinology and Metabolic DiseasesTagsAgingLead InventorBeibei ChenDepartmentMed-MedicineAll Tech InnovatorsBeibei ChenYuan LiuRama K. MallampalliTechnology Readiness Level3. Initial proof of concept, in-vivoDate Submitted2016-04-05CollectionsCardiometabolic
New Methodology Increases NAMPT Activity for Treating Several Diseases including Autoimmune Conditions05563New NAMPT-activating compounds boost NAD+ to treat obesity, autoimmune disorders, aging, kidney injury, and cognitive decline.Technology TypeTherapeutic ModalityTechnology SubtypeSmall MoleculeTherapeutic AreasOncologyEndocrinology and Metabolic DiseasesTherapeutic IndicationsObesityLead InventorBeibei ChenDepartmentMed-MedicineAll Tech InnovatorsBeibei ChenToren FinkelYuan LiuTechnology Readiness Level2. Initial proof of concept, in-vitroDate Submitted2020-11-23CollectionsCardiometabolic
300 Novel CB1 Antagonists Hold Potential for new Treatments05523New, structurally distinct CB1 antagonists offer broad potential for metabolic therapies and weight management. 15 words max, 120-150 characters.Technology TypeTherapeutic ModalityTechnology SubtypeSmall MoleculeTherapeutic AreasNeuroscienceEndocrinology and Metabolic DiseasesTherapeutic IndicationsObesityLead InventorBeibei ChenDepartmentMed-MedicineAll Tech InnovatorsBeibei ChenToren FinkelYuan LiuTechnology Readiness Level2. Initial proof of concept, in-vitroDate Submitted2020-10-06CollectionsCardiometabolic
Novel Activators of AMP-activated Protein Kinase05032Novel AMPK activators block ubiquitin-mediated degradation, boosting AMPK levels with nanomolar potency for metabolic, inflammatory, and cancer therapies.Technology TypeTherapeutic ModalityTechnology SubtypeSmall MoleculeTherapeutic AreasOncologyEndocrinology and Metabolic DiseasesTagsAgingLead InventorBeibei ChenDepartmentMed-MedicineAll Tech InnovatorsBeibei ChenToren FinkelYuan LiuTechnology Readiness Level2. Initial proof of concept, in-vitroDate Submitted2019-06-24CollectionsCardiometabolic
Small Molecules Maintaining NMNAT2 Levels Prevent Degradation04729First-in-class compounds preserve NMNAT2 levels, potentially preventing axon degeneration after injury and in neurodegenerative diseases.Technology TypeTherapeutic ModalityTechnology SubtypeSmall MoleculeTherapeutic AreasNeuroscienceLead InventorBeibei ChenDepartmentMed-MedicineAll Tech InnovatorsBeibei ChenToren FinkelYuan LiuTechnology Readiness Level2. Initial proof of concept, in-vitroDate Submitted2018-09-10
Small-Molecule Stabilizers of TFEB for Local Ocular Delivery in Age-Related Retinal Disease04690Small-molecule GT300 activates TFEB via intravitreal delivery, boosting retinal lysosome autophagy to modulate dry AMD.Technology TypeTherapeutic ModalityTechnology SubtypeSmall MoleculeTherapeutic AreasOphthalmologyTherapeutic IndicationsGlaucomaGeographic atrophyAge-related macular degenerationLead InventorBeibei ChenDepartmentMed-MedicineAll Tech InnovatorsBeibei ChenToren FinkelYuan LiuTechnology Readiness Level4. Pre-clinical developmentDate Submitted2018-07-26
Novel Small Molecule FIEL1 Inhibitor in Inflammatory and Fibrotic Lung Injury03443Novel FIEL1 inhibitor reduces inflammation and fibrosis in lung injury models, offering IPF treatment potential and targeted TGFβ disruption.Technology TypeTherapeutic ModalityTechnology SubtypeSmall MoleculeTherapeutic AreasRespiratoryTherapeutic IndicationsIdiopathic pulmonary fibrosis (IBF)Lead InventorBeibei ChenDepartmentMed-MedicineAll Tech InnovatorsBeibei ChenDate Submitted2014-11-11
Anti-Inflammatory Small Molecules for Treatment of Chronic Inflammatory Disorders04731New small-molecule NF-κB inhibitors target chronic inflammation (asthma, RA, IBD) and may aid aging and cancer therapy.Technology TypeTherapeutic ModalityTechnology SubtypeSmall MoleculeTherapeutic AreasGastroenterologyRespiratoryTherapeutic IndicationsUlcerative ColitisAsthmaLead InventorBeibei ChenDepartmentMed-MedicineAll Tech InnovatorsBeibei ChenToren FinkelYuan LiuTechnology Readiness Level2. Initial proof of concept, in-vitroDate Submitted2018-09-10
